Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2026)

Ginkgo Bioworks Holdings has reported EBITDA for 7 years, with the latest figure at -$83.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 7.51% year-over-year to -$83.2 million; the trailing twelve-month figure through Mar 2026 stood at -$302.3 million (up 35.86% YoY), and the FY2025 full-year result was -$309.1 million, up 43.83% from the prior year.
• EBITDA for Q1 2026 stood at -$83.2 million, down from -$80.9 million in the prior quarter.
• The five-year high for EBITDA was -$54.4 million in Q3 2024, with the low at -$675.4 million in Q1 2022.
• Historically, EBITDA has averaged -$235.0 million across 5 years, with a median of -$168.9 million in 2024.
• The largest YoY upside for EBITDA was 90.04% in 2022 against a maximum downside of 2421.54% in 2022.
• Ginkgo Bioworks Holdings' EBITDA stood at -$167.8 million in 2022, then dropped by 23.55% to -$207.3 million in 2023, then surged by 47.13% to -$109.6 million in 2024, then increased by 26.19% to -$80.9 million in 2025, then declined by 2.9% to -$83.2 million in 2026.
• The last three EBITDA figures came in at -$83.2 million (Q1 2026), -$80.9 million (Q4 2025), and -$80.4 million (Q3 2025), per Business Quant data.